|  |  | Baseline | Six weeks | Change |  |  |
---|---|---|---|---|---|---|---|
Variable | Treat. | N Obs | Median IQR | Median IQR | Median IQR | Contrast1 | P |
Fibrinogen | P | 25 | 312.0 (273.0 to 340.0) | 333.5 (276.0 to 354.0) | 4.5 (-19.0 to 24.0) | T vs. R | 0.02 |
mg/dL | R | 50 | 301.0 (254.0 to 334.0) | 260.0 (230.0 to 288.0) | -29.5 (-61.0 to -5.0) | T + R vs. P | 0.01 |
 | T | 50 | 286.0 (247.0 to 319.0) | 285.0 (243.0 to 312.0) | -2.0 (-20.0 to 12.0) |  |  |
Antithrombin | P | 25 | 102.0 (98.0 to 109.0) | 99.0 (93.0 to 104.0) | -1.0 (-5.0 to 4.0) | T vs. R | 0.75 |
% | R | 50 | 103.0 (98.0 to 108.0) | 94.0 (90.0 to 101.0) | -8.0 (-11.0 to -1.0 | T + R vs. P | 0.02 |
 | T | 50 | 106.0 (98.0 to 114.0) | 100.0 (92.0 to 106.0) | -7.0 (-16.0 to -1.0) |  |  |
CRP | P | 25 | 0.6 (0.3 to 2.8) | 0.8 (0.3 to 3.3) | 0.0 (-0.1 to 0.6) | T vs. R | 0.12 |
mg/dL | R | 50 | 1.0 (0.5 to 1.9) | 0.6 (0.4 to 1.3) | -0.3 (-0.7 to 0.1) | T + R vs. P | 0.21 |
 | T | 50 | 0.7 (0.4 to1.2) | 0.8 (0.4 to 1.3) | 0.1 (-0.3 to 0.3) |  |  |
Cholesterol | P | 25 | 199.0 (185.0 to 224.0) | 225.5 (197.0 to 244.0) | 13.5 (1.0 to 33.0) | T vs. R | 0.30 |
mg/dL | R | 50 | 199.5 (179.0 to 222.0) | 192.0 (168.0 to 215.0) | -7.0 (-23.0 to 5.0) | T + R vs. P | <.0001 |
 | T | 50 | 201.5 (180.0 to 220.0) | 188.5 (171.0 to 200.0) | -12.0 (-18.0 to 0.0) |  |  |
CTX ng/mL | P | 25 | 0.3 (0.2 to 0.4) | 0.3 (0.2 to 0.3) | 0.0 (-0.1 to 0.0) | T vs. R | 0.05 |
 | R | 50 | 0.3 (0.2 to 0.4) | 0.3 (0.2 to 0.4) | 0.0 (0.0 to 0.1) | T + R vs. P | 0.58 |
 | T | 50 | 0.3 (0.2 to 0.4) | 0.3 (0.2 to 0.4) | 0.0 (-0.1 to 0.0) |  |  |
Osteocalcin | P | 25 | 16.9 (13.4 to20.3) | 16.5 (13.1 to 22.5) | -0.5 (-1.9 to 2.2) | T vs. R | 0.39 |
ng/mL | R | 50 | 17.9 (13.8 to 22.5) | 16.8 (13.4 to 20.8) | -1.7 (-3.5 to 1.1) | T + R vs. P | 0.32 |
 | T | 50 | 16.0 (61.98 to 165.5) | 15.3 (12.5 to 20.2) | -0.7 (-2.0 to 1.0) |  |  |